Sort by
Previous Page Page 1 of 1 Next Page
  1. Review

    Management of atrial fibrillation in patients taking targeted cancer therapies

    Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, seve...

    Aarti Asnani, Anastasia Manning, Moussa Mansour, Jeremy Ruskin, Ephraim P. Hochberg and Leon M. Ptaszek

    Cardio-Oncology 2017 3:2

    Published on: 9 March 2017

  2. Research

    Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity

    Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung canc...

    Zhushan Zhang, Tai-Qin Huang, Igor Nepliouev, Hengtao Zhang, Adam S. Barnett, Paul B. Rosenberg, Sai-Hong I. Ou and Jonathan A. Stiber

    Cardio-Oncology 2017 3:1

    Published on: 19 January 2017

  3. Short communication

    Cardiovascular co-morbidity in cancer patients: the role of psychological distress

    Due to aging of the population and cardiotoxic cancer treatment, there is an increasing group of patients with cancer and co-morbid cardiovascular disease (CVD). In order to find a balance between the risk of ...

    Dounya Schoormans, Susanne S. Pedersen, Susanne Dalton, Nina Rottmann and Lonneke van de Poll-Franse

    Cardio-Oncology 2016 2:9

    Published on: 15 November 2016

  4. Research

    A comparative assessment of coronary artery calcification on chest CT scans of patients referred to a cardio-oncology clinic

    The presence and burden of coronary artery calcium (CAC) is a strong predictor of cardiovascular events. In an effort to gain insight into the utility of CAC for coronary artery disease (CAD) screening in canc...

    Alison M. Brann, Charlotte J. Bai, John F. Hibbeln, Kim A. Williams and Tochi M. Okwuosa

    Cardio-Oncology 2016 2:7

    Published on: 6 October 2016

  5. Research

    Persistent PR segment change in malignant pericardial disease

    Electrocardiographic changes may manifest in patients with pericardial effusions. PR segment changes are frequently overlooked, but when present, can provide diagnostic significance. The diagnostic value of PR...

    M. Ahluwalia, R. O’Quinn, B. Ky, D. Callans, J. Kucharczuk and J. R. Carver

    Cardio-Oncology 2016 2:6

    Published on: 14 July 2016

  6. Review

    Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic

    The diagnosis and management of cardiovascular complications have become a clinical concern for oncologists, cardiologists, surgeons, interventional radiologists, radiation therapy physicians, internists, nurs...

    Sergio Barros-Gomes, Joerg Herrmann, Sharon L. Mulvagh, Amir Lerman, Grace Lin and Hector R. Villarraga

    Cardio-Oncology 2016 2:5

    Published on: 19 April 2016

  7. Research

    The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity

    Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to c...

    Beshay N. Zordoky, M. Judith Radin, Lois Heller, Anthony Tobias, Ilze Matise, Fred S. Apple, Sylvia A. McCune and Leslie C. Sharkey

    Cardio-Oncology 2016 2:4

    Published on: 15 March 2016

  8. Review

    Doxorubicin cardiotoxicity and target cells: a broader perspective

    The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication ...

    Antonella De Angelis, Konrad Urbanek, Donato Cappetta, Elena Piegari, Loreta Pia Ciuffreda, Alessia Rivellino, Rosa Russo, Grazia Esposito, Francesco Rossi and Liberato Berrino

    Cardio-Oncology 2016 2:2

    Published on: 3 March 2016

  9. Review

    Hypertension in cancer patients treated with anti-angiogenic based regimens

    New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular ...

    Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky and Zaza Iakobishvili

    Cardio-Oncology 2015 1:6

    Published on: 7 December 2015

  10. Review

    Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia

    Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improvi...

    Oren Pasvolsky, Avi Leader, Zaza Iakobishvili, Yishay Wasserstrum, Ran Kornowski and Pia Raanani

    Cardio-Oncology 2015 1:5

    Published on: 4 December 2015

  11. Review

    Cardiac safety of afatinib: a review of data from clinical trials

    Afatinib is an oral irreversible ErbB family blocker that targets epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and HER4 (ErbB4) and is approved for the ...

    Michael S. Ewer, Kalpesh Patel, Dennis O’Brien and Robert M. Lorence

    Cardio-Oncology 2015 1:3

    Published on: 26 November 2015

  12. Research

    Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy

    Subacute cardiotoxicity, consisting of acute myocyte damage and associated left ventricular dysfunction, occurs early during anthracycline therapy. We investigated the impact of myocardial dysfunction, defined...

    Olga H. Toro-Salazar, Eileen Gillan, Joanna Ferranti, Andrea Orsey, Karen Rubin, Shailendra Upadhyay, Wojciech Mazur and Kan N. Hor

    Cardio-Oncology 2015 1:1

    Published on: 26 November 2015

Previous Page Page 1 of 1 Next Page